REG - Advanced Oncotherapy - Holding(s) in Company

Advanced OncotherapyAnnouncement

28/11/2019 10:15

RNS Number : 9994U
Advanced Oncotherapy PLC
28 November 2019
 


28 November 2019
 
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
 
Holding in Company
 
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, was informed on 28 November 2019 that Mr Philippe Glatz now has a total interest in 15,659,162 ordinary shares of 25 pence each, equivalent to 6.42% of the Company's issued ordinary share capital.
 
 




 Advanced Oncotherapy plc


www.avoplc.com




 Dr. Michael Sinclair, Executive Chairman


Tel: +44 (0) 20 3617 8728




 Nicolas Serandour, CEO
 
 


 




 


 




 Allenby Capital Limited (Nomad & Broker)


 




 Nick Athanas / Liz Kirchner / Nicholas Chambers
 
 


Tel: +44 (0) 20 7601 6100




 


 




 FTI Consulting (Financial PR & IR)


advancedoncotherapy@fticonsulting.com




 Simon Conway / Rob Winder


Tel: +44 (0) 20 3727 1000




 
Notes for Editors
 
About Advanced Oncotherapy Plc - www.avoplc.com
 
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
 
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
 
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUWARRKRAAUAA